IL244971B2 - Diagnostic methods and systems for irritable bowel syndrome and inflammatory bowel disease - Google Patents

Diagnostic methods and systems for irritable bowel syndrome and inflammatory bowel disease

Info

Publication number
IL244971B2
IL244971B2 IL244971A IL24497116A IL244971B2 IL 244971 B2 IL244971 B2 IL 244971B2 IL 244971 A IL244971 A IL 244971A IL 24497116 A IL24497116 A IL 24497116A IL 244971 B2 IL244971 B2 IL 244971B2
Authority
IL
Israel
Prior art keywords
biological sample
vinculin
ibs
antibodies
cdt
Prior art date
Application number
IL244971A
Other languages
English (en)
Hebrew (he)
Other versions
IL244971B1 (en
IL244971A0 (en
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52813648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL244971(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of IL244971A0 publication Critical patent/IL244971A0/en
Publication of IL244971B1 publication Critical patent/IL244971B1/en
Publication of IL244971B2 publication Critical patent/IL244971B2/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/487Physical analysis of biological material of liquid biological material
    • G01N33/49Blood
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • G01N2800/065Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ecology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
IL244971A 2013-10-09 2014-10-09 Diagnostic methods and systems for irritable bowel syndrome and inflammatory bowel disease IL244971B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361888658P 2013-10-09 2013-10-09
PCT/US2014/059957 WO2015054529A1 (en) 2013-10-09 2014-10-09 Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease

Publications (3)

Publication Number Publication Date
IL244971A0 IL244971A0 (en) 2016-05-31
IL244971B1 IL244971B1 (en) 2023-08-01
IL244971B2 true IL244971B2 (en) 2023-12-01

Family

ID=52813648

Family Applications (1)

Application Number Title Priority Date Filing Date
IL244971A IL244971B2 (en) 2013-10-09 2014-10-09 Diagnostic methods and systems for irritable bowel syndrome and inflammatory bowel disease

Country Status (19)

Country Link
US (2) US9851361B2 (OSRAM)
EP (1) EP3054977B1 (OSRAM)
JP (1) JP6567509B2 (OSRAM)
KR (1) KR102259588B1 (OSRAM)
CN (1) CN105744956B (OSRAM)
AU (2) AU2014331841B2 (OSRAM)
BR (1) BR112016007474A2 (OSRAM)
CA (1) CA2923651C (OSRAM)
CL (1) CL2016000820A1 (OSRAM)
ES (1) ES2892905T3 (OSRAM)
IL (1) IL244971B2 (OSRAM)
MX (1) MX383423B (OSRAM)
NZ (1) NZ717633A (OSRAM)
PE (1) PE20160882A1 (OSRAM)
PL (1) PL3054977T3 (OSRAM)
PT (1) PT3054977T (OSRAM)
RU (1) RU2683781C2 (OSRAM)
SG (1) SG11201601733VA (OSRAM)
WO (1) WO2015054529A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010213708B2 (en) 2009-02-11 2015-12-10 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
AU2013315981B2 (en) 2012-09-17 2019-04-18 Cedars-Sinai Medical Center Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia
PE20160882A1 (es) 2013-10-09 2016-09-14 Cedars Sinai Medical Center Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal
KR102426541B1 (ko) 2014-10-09 2022-07-29 세다르스-신나이 메디칼 센터 과민성 장 증후군을, 염증성 장 질환 및 셀리악 병과 구별하기 위한 방법 및 시스템
CN106053827A (zh) * 2016-05-17 2016-10-26 上海凯璟生物科技有限公司 一种肠易激综合症标志物Vinculin抗体检测试剂盒及其制备方法
CN105784989A (zh) * 2016-05-17 2016-07-20 上海凯璟生物科技有限公司 一种肠易激综合症标志物CdtB抗体检测试剂盒及其制备方法
JP7475811B2 (ja) * 2016-05-20 2024-04-30 シーダーズ―シナイ メディカル センター 遺伝子に基づく炎症性腸疾患の診断
KR20190111094A (ko) 2017-01-30 2019-10-01 세다르스-신나이 메디칼 센터 경피증의 진단
RU2763258C1 (ru) * 2020-07-13 2021-12-28 Евгения Николаевна Воронина Способ дифференциальной диагностики воспалительных заболеваний кишечника у детей по комплексу клинико-анамнестических, лабораторных и инструментальных критериев

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018528A1 (en) * 2002-05-17 2004-01-29 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
US20110305704A1 (en) * 2009-02-11 2011-12-15 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of campylobacter jejuni

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
FR2806805A1 (fr) 2000-03-22 2001-09-28 Centre Nat Rech Scient SEQUENCE PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS
EP2444409A2 (en) 2002-09-16 2012-04-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7595386B2 (en) 2003-01-24 2009-09-29 William Beaumont Hospital Methods and compositions for heat activated gene therapy using cytolethal distending toxin
CA2521369A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
EP2280285A1 (en) * 2003-09-15 2011-02-02 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
PT1698698E (pt) 2003-12-05 2014-03-06 Fuso Pharmaceutical Ind Genes da toxina distensora citoletal como alvos para a deteção de bactérias campylobacter
US8148067B2 (en) 2006-11-09 2012-04-03 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
PL2223121T3 (pl) 2007-12-20 2012-12-31 Index Diagnostics Ab Publ Sposób różnicowania NZJ i ZJD oraz dalsze rozróżnienie odmian NZJ
ES2529060T3 (es) 2008-11-24 2015-02-16 Cedars-Sinai Medical Center Derivados antioxidantes de la camptotecina y nanoesferas antineoplásicas antioxidantes de los mismos
WO2010093776A1 (en) 2009-02-11 2010-08-19 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
FR2942541A1 (fr) 2009-02-25 2010-08-27 Assist Publ Hopitaux De Paris Procede de diagnostic d'une vascularite
RU2397178C1 (ru) * 2009-02-27 2010-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Диагностическая тест-система в формате иммуночипа и способ серологической дифференциальной диагностики сифилиса
IT1400989B1 (it) 2010-07-13 2013-07-05 Segix Italia S R L Ora Istituto Biochimico Naz Savio S R L Forme di somministrazione orale a rilascio controllato di rifampicina per il trattamento di infezioni batteriche dell' apparato intestinale.
GB201017520D0 (en) 2010-10-15 2010-12-01 Sense Proteomic Ltd Biomarkers
AU2013315981B2 (en) * 2012-09-17 2019-04-18 Cedars-Sinai Medical Center Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia
PE20160882A1 (es) 2013-10-09 2016-09-14 Cedars Sinai Medical Center Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal
KR102426541B1 (ko) 2014-10-09 2022-07-29 세다르스-신나이 메디칼 센터 과민성 장 증후군을, 염증성 장 질환 및 셀리악 병과 구별하기 위한 방법 및 시스템
CN106091069A (zh) 2016-06-15 2016-11-09 安徽省绿巨人环境技术有限公司 一种废水再利用装置
KR20190111094A (ko) 2017-01-30 2019-10-01 세다르스-신나이 메디칼 센터 경피증의 진단

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018528A1 (en) * 2002-05-17 2004-01-29 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
US20110305704A1 (en) * 2009-02-11 2011-12-15 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of campylobacter jejuni

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MORALES W. ET AL.,, MORALES 2013, 31 March 2013 (2013-03-31) *

Also Published As

Publication number Publication date
EP3054977A1 (en) 2016-08-17
PE20160882A1 (es) 2016-09-14
CN105744956A (zh) 2016-07-06
KR20160062161A (ko) 2016-06-01
RU2016116766A (ru) 2017-11-15
AU2020203468A1 (en) 2020-06-18
ES2892905T3 (es) 2022-02-07
US20170038393A1 (en) 2017-02-09
MX2016004167A (es) 2016-06-24
US9851361B2 (en) 2017-12-26
RU2683781C2 (ru) 2019-04-02
MX383423B (es) 2025-03-14
CL2016000820A1 (es) 2016-09-23
IL244971B1 (en) 2023-08-01
NZ717633A (en) 2021-07-30
WO2015054529A1 (en) 2015-04-16
EP3054977A4 (en) 2017-04-12
CA2923651A1 (en) 2015-04-16
KR102259588B1 (ko) 2021-06-02
AU2014331841A1 (en) 2016-03-24
PL3054977T3 (pl) 2021-12-20
AU2014331841B2 (en) 2020-03-12
EP3054977B1 (en) 2021-07-21
CN105744956B (zh) 2021-07-20
JP2017502253A (ja) 2017-01-19
US10352944B2 (en) 2019-07-16
US20180196063A1 (en) 2018-07-12
BR112016007474A2 (pt) 2017-09-12
CA2923651C (en) 2023-03-14
HK1221898A1 (zh) 2017-06-16
SG11201601733VA (en) 2016-04-28
JP6567509B2 (ja) 2019-08-28
PT3054977T (pt) 2021-10-14
IL244971A0 (en) 2016-05-31

Similar Documents

Publication Publication Date Title
IL244971B2 (en) Diagnostic methods and systems for irritable bowel syndrome and inflammatory bowel disease
US10466254B2 (en) Method of measuring a level of anti-vinculin antibodies in a biological sample
US10690679B2 (en) Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
US12222352B2 (en) Diagnosis of scleroderma
US20240159772A1 (en) Methods for Detecting and Treating Irritable Bowel Syndrome
HK1221898B (en) Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease
HK1207420B (en) Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia